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Purpose: Retinitis pigmentosa (RP) is a group of inherited retinal degenerations leading to blindness due to
photoreceptor loss. Retinitis pigmentosa is a rare disease, affecting only approximately 100 000 people in the
United States. There is no cure and no approved medical therapy to slow or reverse RP. The purpose of this
clinical trial was to evaluate the safety, reliability, and beneﬁt of the Argus II Retinal Prosthesis System (Second
Sight Medical Products, Inc, Sylmar, CA) in restoring some visual function to subjects completely blind from RP.
We report clinical trial results at 1 and 3 years after implantation.
Design: The study is a multicenter, single-arm, prospective clinical trial.
Participants: There were 30 subjects in 10 centers in the United States and Europe. Subjects served as their
own controls, that is, implanted eye versus fellow eye, and system on versus system off (native residual vision).
Methods: The Argus II System was implanted on and in a single eye (typically the worse-seeing eye) of blind
subjects. Subjects wore glasses mounted with a small camera and a video processor that converted images into
stimulation patterns sent to the electrode array on the retina.
Main Outcome Measures: The primary outcome measures were safety (the number, seriousness, and
relatedness of adverse events) and visual function, as measured by 3 computer-based, objective tests.
Results: A total of 29 of 30 subjects had functioning Argus II Systems implants 3 years after implantation.
Eleven subjects experienced a total of 23 serious device- or surgery-related adverse events. All were treated with
standard ophthalmic care. As a group, subjects performed signiﬁcantly better with the system on than off on all
visual function tests and functional vision assessments.
Conclusions: The 3-year results of the Argus II trial support the long-term safety proﬁle and beneﬁt of the Argus
II System for patients blind from RP. Earlier results from this trial were used to gain approval of the Argus II by the
Food and Drug Administration and a CE mark in Europe. The Argus II System is the ﬁrst and only retinal implant to
have both approvals. Ophthalmology 2015;122:1547-1554ª 2015 by theAmericanAcademy ofOphthalmology. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Supplemental material is available at www.aaojournal.org.This study presents 3-year results from the ongoing clinical
trial of the Argus II Retinal Prosthesis System (Second Sight
Medical Products, Inc., Sylmar, CA). The study’s purpose is to
evaluate the safety and beneﬁt of the Argus II System in
providing functional vision to people blind from retinitis pig-
mentosa (RP).
Several different approaches to restoring sight to those
blind from retinal degeneration are currently under investi-
gation, including stem cell therapy,1 gene therapy,2,3 and
other approaches.4 Visual prostheses offer the possibility of
restoring vision in patients who are severely blinded from
RP and other retinal degenerations. Different visual
prostheses have been explored, including visual cortex,5,6
optic nerve,7 epiretinal,8 and subretinal9 devices. Although 2015 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Published by Elsevier Inc.many approaches show promise, to date, retinal prostheses
are the only therapy to have achieved market approval
in the United States and Europe. A previous report8
presented data from this cohort when all subjects had
reached 6 months of follow-up. We present complete
1-year and 3-year data from the Argus II clinical trial.Methods
Study Design
The study is a single-arm, prospective, unmasked clinical trial.
Because of the rarity of the eligible patient population, the sample
size was 30 subjects, which was determined, with guidance from1547http://dx.doi.org/10.1016/j.ophtha.2015.04.032
ISSN 0161-6420/15
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power to evaluate safety and probable beneﬁt. These 30 subjects
were enrolled at 10 centers in the United States and Europe.
Subjects served as their own controls (i.e., tested with the Argus II
System turned on vs. using only their residual vision). The trial
was and continues to be conducted in accordance with the
Declaration of Helsinki and the national regulations for medical
device clinical trials in the respective countries where the study is
being conducted. The study has been approved by the national
ministries of health in these countries and the ethics committees or
institutional review boards of participating institutions. All sub-
jects signed informed consent to participate. The clinical trial is
posted on www.clinicaltrials.gov, trial registration number
NCT00407602.
Inclusion and Exclusion Criteria
Subjects were eligible to enroll if they had a conﬁrmed diagnosis of
RP (United States) or outer retinal degeneration (Europe), bare or
no light perception in both eyes, functional ganglion cells or optic
nerve (conﬁrmed by photoﬂash detection or measurable electrically
evoked response), and a history of useful form vision. Age inclu-
sion criterion was initially 50 years and was later changed to 25
years in the United States and Switzerland and 18 years in France
and the United Kingdom.
Exclusion criteria included diseases or conditions that affected
retinal or optic nerve function, ocular structures, or conditions that
could prevent successful implantation, and any inability to tolerate
the implant surgery or medical/study follow-up. Full inclusion and
exclusion criteria are listed at www.clinicaltrials.gov.
Device
The Argus II System consists of an active device implanted on and
in the eye and external equipment worn by the user. The implanted
portion of the system includes a receiving antenna and an elec-
tronics case that are ﬁxed outside the eye with sutures and a scleral
band, and an intraocular 6  10 electrode array that is tacked over
the macula epiretinally (i.e., on the retinal ganglion cell side)
(Fig 1A). The external portion of the system includes a glasses-
mounted video camera and a small video processing unit (VPU)
(Fig 1B) that can be worn on a shoulder strap or belt (not shown).
The camera collects visual information and sends it to the VPU,
which down-samples and processes the image. Several buttons
on the VPU allow user control of various image-processing algo-
rithms, for example, enhancing contrast. Data and power are sent
wirelessly from a transmitting antenna on the glasses to the internal
receiving antenna. The electrodes in the array emit pulses of
electricity whose amplitude corresponds to the brightness of the
scene in that location. Stimulation of the remaining retinal cells
induces cellular responses that travel through the proximal visual
system, resulting in visual percepts that subjects learned to
interpret.
Surgical Procedure
Subjects received the Argus II Retinal Prosthesis System in 1 eye,
typically the worse-seeing eye. The surgical procedure is summa-
rized as follows; a more detailed description of the procedure and
medication regimen is in the online Appendix (available at
www.aaojournal.org).
To implant the device, a 360-degree limbal conjunctival peri-
tomy was performed. The rectus muscles were isolated, and the
coil was inserted temporally on the globe and centered under the
lateral rectus muscle. The electronics package was centered in the
superotemporal quadrant. The inferior part of the scleral band was
passed under the inferior and the medial rectus muscles, and the1548superior portion of the band under the superior rectus muscle. The
implant was ﬁxed to the eye via sutures passed through suture tabs
on the implant in both temporal quadrants, and a Watzke sleeve
(Labtician Ophthalmics, Inc, Oakville, Ontario, Canada) and
mattress sutures or scleral tunneling were used to secure the scleral
band in the nasal quadrants.
A core and peripheral vitrectomy were conducted. The array
was then inserted through a temporal sclerotomy. The electrode
array was placed on the retina in the macular region and then
tacked using a custom retinal tack (Second Sight Medical Products,
Inc, Sylmar, CA). The extraocular portion of the cable was sutured
to the sclera, and all sclerotomies were closed.
An allograft (or suitable alternative in countries where allografts
were not permitted) was ﬁxed over the device to reduce the like-
lihood of conjunctival irritation. Finally, the Tenon’s capsule and
the conjunctiva were closed.
Assessment of Safety: Primary End Point
All adverse events were collected and reported as necessary to the
relevant authorities and ethics committees. Adverse events were
classiﬁed by relatedness (device- or surgery-related, or subject-
related) and whether they met the regulatory deﬁnition of
“serious” (i.e., adverse events that required medical or surgical
intervention or hospitalization to prevent permanent injury).
Serious adverse events (SAEs) were distinguished from those for
which treatment was unnecessary or noninvasive (nonserious).
Therefore, a particular type of adverse event, such as hypotony,
may have been considered nonserious or serious, depending on
how or whether that particular event was treated. All adverse
events were subject to detailed review and adjudication by an in-
dependent medical safety monitor.
Assessment of Visual Function: Primary End Point
The primary end point for the evaluation of beneﬁt was visual
function. This was assessed with 3 computer-based, objective tests
of basic visual skills developed by Second Sight with input from
the low-vision research community to cover the range of low vision
restored by a retinal implant.
In “Square Localization,” subjects had to locate and touch a
white square in random locations on a black touchscreen monitor.
The response error (the distance between the subject’s response
and the center of the target square in centimeters) was recorded and
averaged over 40 trials. The mean error with the system on and off
for each subject was evaluated with a 2-tailed t test assuming un-
equal variances to determine whether the on and off results were
signiﬁcantly different.
In “Direction of Motion,” a white bar moved across the same
black touch screen and subjects drew the direction they perceived
the bar to be moving. The response error (the difference between
the subject’s response angle and the target bar’s angle in degrees)
was recorded and averaged over 80 trials. A 2-tailed t test was
performed to determine whether the mean errors with the system
on and off were signiﬁcantly different.
Finally, “Grating Visual Acuity” measured subjects’ visual
acuity on a scale of 2.9 to 1.6 logarithm of the minimum angle of
resolution (logMAR) (20/15887e20/796 in Snellen notation) using
black and white gratings displayed for 5 seconds. In a 4-alternative
forced-choice test, subjects indicated the perceived orientation
(horizontal, vertical, diagonal left/right); the program adaptively
reduced or increased the spatial frequency of the gratings on the
basis of the number of correct and incorrect answers. Subjects
whose performance was no better than chance were scored as
acuity “worse than 2.9 logMAR.”
Figure 1. A, The implanted portions of the Argus II System (Second Sight
Medical Products, Inc., Sylmar, CA). B, The external components of the
Argus II System. Images in real time are captured by the camera mounted
on the glasses. The video processing unit down-samples and processes the
image, converting it to stimulation patterns. Data and power are sent via
radiofrequency link from the transmitter antenna on the glasses to the
receiver antenna around the eye. A removable, rechargeable battery powers
the system.
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Point
Device stability and reliability were tracked by 2 measures: number
of explants (surgical removal of all or a portion of the implanted
device) and number of device failures (inability of the device to
function).
Assessments of Orientation and Mobility, Activities
of Daily Living, and Quality of Life: Secondary End
Points
Assessments of performance in more real-world conditions were
made with indoor orientation and mobility tasks involving ﬁnding
and touching a “door” and following a white line on the ﬂoor. In
the “Door Task,” subjects walked across a room and tried to ﬁnd
and touch a simulated door (black cloth on a light wall, in 1 of 2
positions relative to the subject’s starting point). In the “Line
Task,” subjects walked across a ﬂoor consisting of black rubber
interlocking tiles. A 6-inch-wide white line painted on the tiles was
conﬁgured to be straight or to have a 90 turn to the left or right.
Six trials were performed with the system on and off, and successes
(touching the door or ending on the line at its end point) or failures
and time to completion were recorded. Detailed methods have been
described.8
At the beginning of the study, patient-reported activities of
daily living and quality of life were assessed with the VisQoLvision-related utility instrument10 and the Mass of Activity
Inventory.11 These instruments were not fully validated in
patients with RP with minimal or no sight and thus were used
primarily for exploratory purposes in this study (data not shown).
Patient-reported outcomes from this study will be reported in the
future.
To evaluate the impact of the Argus II System on subjects’
everyday lives, the Functional Low-vision Observer Rated
Assessment (FLORA) was developed at the request of and with
input from the US Food and Drug Administration (FDA) and
introduced partway through the trial. The FLORA was performed
by independent visual rehabilitation experts to subjectively assess
real-world beneﬁt of the Argus II System. Assessors ﬁrst
performed an extensive interview to understand a subject’s self-
reported experience with the Argus II System. Next, the asses-
sors observed the subject performing visual tasks (system on and
off) in and around his or her home. Tasks were chosen by the
assessors from a provided list and included orientation and
mobility tasks, activities of daily living, and social interactions.
Finally, the assessor wrote a case study narrative to synthesize his
or her judgment of the effect of the Argus II on that subject’s life,
taking into account both real-world use and quality of life. All
narratives then were rated by a single independent rater for the
effect of the system on subjects’ lives: positive, mild positive
(usually subjects who self-reported functional beneﬁts that were
not supported by assessors’ observations), prior positive (subjects
who self-reported positive effects in the past that could not be
demonstrated at the time of the assessment), neutral, and negative.
Performance was assessed on all subjects at months 3 and 6,
and years 1 to 3, except the FLORA, which was performed at years
1 and 3. The number of subjects assessed by each test differed
slightly because of the introduction of Square Localization and
Direction of Motion tests partway through the trial, as well as some
missed follow-up visits. Deviations were collected and reported to
relevant regulatory agencies.Results
A total of 30 subjects received the Argus II System between June
2007 and August 2009 at 10 different centers in the United States
and Europe. Twenty-nine subjects had RP (including 1 with Leber
congenital amaurosis), and 1 subject had choroideremia. Twenty-
nine subjects had bare light perception (i.e., the ability to detect
very bright light) in both eyes, and 1 subject had no light
perception (but was able to perceive light in response to trans-
corneal electrical stimulation). The age at time of implant ranged
from 28 to 77 years (average 58 years, standard deviation 10
years). There were 9 female and 21 male subjects. Median surgery
time was 4:04 hours (range, 1:53e8:32 hours).Safety
As of 1 year after implantation, 66.7% of subjects (20/30) had
experienced no device- or surgery-related SAEs. There were 18
SAEs among 10 subjects. The SAEs fell into 10 types, with
hypotony, conjunctival dehiscence, conjunctival erosion, and pre-
sumed endophthalmitis (culture negative) being slightly more
common than the others. There were also 2 subjects who under-
went revision surgery to re-tack the array to the retina 1 week after
implantation.
At 3 years after implantation, there were a total of 23 SAEs
among 11 subjects, with 2 additional SAE types. One subject’s
device was removed at 1.2 years to treat recurrent conjunctival
erosion, as reported previously.8 Table 1 shows the total percentage1549
Table 1. Percent of Subjects (N¼ 30) Experiencing Each Serious Adverse Event Type with 95% Conﬁdence Intervals through Year 1 and
Year 3 after Implantation (Cumulative)
SAE Type
Year 1 Year 3
No. of Subjects
with SAE
% of Subjects
with SAE 95% CI
No. of Subjects
with SAE
% of Subjects
with SAE 95% CI
Conjunctival erosion 3 10.0% 2.1e26.5 4 13.3% 3.1e30.7
Hypotony 2 6.7% 0.8e22.1 4 13.3% 3.1e30.7
Conjunctival dehiscence 3 10.0% 2.1e26.5 3 10.0% 2.1e26.5
Presumed endophthalmitis 3 10.0% 2.1e26.5 3 10.0% 2.1e26.5
Re-tack 2 6.7% 0.8e22.1 2 6.7% 0.8e22.1
Corneal opacity 1 3.3% 0.1e17.2 1 3.3% 0.1e17.2
Retinal detachmentdrhegmatogenous 1 3.3% 0.1e17.2 1 3.3% 0.1e17.2
Retinal detachmentdtractional and serous 1 3.3% 0.1e17.2 1 3.3% 0.1e17.2
Retinal tear 1 3.3% 0.1e17.2 1 3.3% 0.1e17.2
Uveitis 1 3.3% 0.1e17.2 1 3.3% 0.1e17.2
Keratitisdinfective 0 0.0% 0.0 1 3.3% 0.1e17.2
Corneal melt 0 0.0% 0.0 1 3.3% 0.1e17.2
CI ¼ conﬁdence interval; SAE ¼ serious adverse event.
Ophthalmology Volume 122, Number 8, August 2015of subjects experiencing each SAE type with the 95% conﬁdence
intervals for data through year 1 and year 3.
Serious adverse events were clustered toward the early post-
operative period: 14 of 23 SAEs (61%) occurred within the ﬁrst 6
months after implantation, and only 5 SAEs (among 4 subjects)
occurred after month 12. These late SAEs were 2 cases of hypotony
and 1 each of keratitisdinfective, corneal melt, and conjunctival
erosion. This trend also held for non-SAEs; more than half (53%)
of all non-SAEs occurred within the ﬁrst 6 months. Events were
also clustered within patients; 3 subjects (10%) accounted for more
than 55% of SAEs by 3 years after implantation, and 19 subjects
had experienced no SAEs by that time. Indeed, 4 of the SAEs that
occurred after year 1 were part of cascades or recurrences of events
in 3 subjects. Only 1 SAE after year 1, a case of hypotony, occurred
in a subject who had not previously experienced any SAEs. All
SAEs were treatable with standard ophthalmic approaches, and
there were no lost eyes (enucleated) in the study. A full listing and
percentages of non-SAEs are in the online Appendix (available at
www.aaojournal.org). Of note are 7 subjects who underwent
elective revision surgeries, which involved attempts to improve
the position of the array.
Visual Function
At both 1 and 3 years, in the Square Localization test, a majority of
subjects performed signiﬁcantly better with the system on than off;
in the Direction of Motion test, more than half of the subjects
performed signiﬁcantly better with the system on; on Grating Vi-
sual Acuity, no subjects scored on the scale with their fellow eye
(system off), whereas 33% to 48% of the subjects scored 2.9
logMAR or better with the system on (year 3 and year 1, respec-
tively) (Table 2). The mean acuity values of those who scored on
the scale were 2.5 logMAR (standard deviation, 0.3 logMAR) at
year 1 and 2.5 logMAR (standard deviation, 0.4 logMAR) at
year 3. The best score at these 2 time points was 1.9 logMAR
(20/1588). As previously reported,8 1 subject scored 1.8
logMAR on this test at a different time point.
Device Reliability
Twenty-nine subjects still had functioning devices 3 years after
implantation. The 1 explant was due to SAE management, rather1550than device failure. There were no device failures through the 3-
year follow-up.
Orientation and Mobility, Activities of Daily Living,
and Quality of Life
On both the Door and Line tasks, subjects perform better (higher
mean percent success) when using their Argus II Systems
(Table 2). On the FLORA, the effect of the system was
overwhelmingly rated as positive or mild positive compared with
prior positive or neutral at both year 1 and year 3; there were no
ratings of negative at either time point (Table 2).
Discussion
The Argus II System was extremely reliable and stable, with
no device failures within 3 years after implantation (a total
of 88.2 subject-years). Some of the performance measures
(Square Localization, Direction of Motion, Grating Visual
Acuity, and the FLORA) seem to show a smaller percentage
of subjects performing better with the system on than off
(Table 2). It is unclear whether this is a true performance
decline, but that is a possibility. Most of these measures
(except Grating Visual Acuity) were introduced partway
through the clinical trial, after year 1 for approximately
half the subjects. Therefore, the year 3 results include
more subjects who received implants earlier in the trial; a
possible explanation could be that subjects enrolled later
(who received a slightly different array design) were better
performers. This is supported by the results on the Find
the Door and Follow the Line tasks (Table 2), which
show essentially equal performance at years 1 and 3
among the same group of 28 subjects.
Visual function results indicated that 89% of subjects
performed signiﬁcantly better with the system on than off
for Square Localization at 3 years after implantation, 56%
for Direction of Motion, and 33% scored on the scale on
Grating Visual Acuity with the system on (no subjects
scored with the system off). Similar proportions of system
Table 2. Assessments of Beneﬁt
A Year 1 Year 3
Outcome Measure N % Signiﬁcantly Better on than off N % Signiﬁcantly Better on than off
Square Localization 16 93.8% 28 89.3%
Direction of Motion 16 62.5% 27 55.6%
Grating Visual Acuity 29 48.2% 27 33.3%
B
Outcome Measure N Mean (SD) % Success on Mean (SD) % Success off N Mean (SD) % Success on Mean (SD) % Success off
Find the Door 28 53.0% (5.5%) 30.8% (4.8%) 28 54.2% (6.2%) 19.0% (4.3%)
Follow the Line 28 72.8% (5.7%) 17.1% (4.2%) 28 67.9% (6.5%) 14.3% (3.8%)
C
Outcome Measure N
% Positive and
Mild Positive
% Prior Positive
and Neutral Negative N
% Positive and
Mild Positive
% Prior Positive
and Neutral Negative
FLORA 15 80% 20% 0 23 65.20% 34.80% 0
Panel A shows visual function results (primary end point). Results for Square Localization and Direction of Motion indicate the percentage of subjects whose
system on results were signiﬁcantly different from (better than) system off. Results for Grating Visual Acuity indicate the percentage of subjects who scored
between 2.9 and 1.6 logMARwith the system on. None of the subjects scored with the system off. The proportion of subjects with signiﬁcantly better system on
than off results was not signiﬁcantly different between 1 and 3 years for any of the visual function tests (P > 0.05, z test). Panel B shows the mean percentage
success on the Find the Door and Follow the Line orientation andmobility assessments. Panel C shows the results of the Functional Low-vision Observer Rated
Assessment (FLORA) at year 1 and year 3.
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sets earlier in the clinical trial8,12,13; these latest results
indicate that visual function beneﬁt from the Argus II Sys-
tem is sustained to at least 3 years after implantation. For the
33% to 48% of subjects who scored on the Grating Visual
Acuity scale with their systems on, the mean visual acuity
was 2.5 logMAR. Because none of these subjects had visual
acuity of 2.9 logMAR or better with the system off, this
result would be equivalent to an average gain of at least 4
lines on the Early Treatment Diabetic Retinopathy Study
(ETDRS) chart for these patients.
Laboratory-based orientation and mobility tests (Find the
Door and Follow the Line) provide additional evidence that the
system provided long-term beneﬁt; subjects were able to
perform practical tasks with more success with the system on
than off to 3 years after implantation. Finally, an in-depth
assessment of subjects’ functional vision and well-being (theTable 3. Serious Adverse Event Rates for the Argus II System
Comparator
Adverse Event Retinal Tack
Hypotony
Conjunctival dehiscence
Conjunctival erosion
Presumed endophthalmitis (culture-negative)
Dislodged tack 5.3% (1.1e15.4)18
NR ¼ not reported.
Adverse event rates at 1 year (with 95% conﬁdence intervals in brackets) as re
adverse events that occurred in >1 Argus II subject. The follow-up time reportedFLORA), performed by independent rehabilitation specialists,
found that 80% subjects received beneﬁt from the system at 1
year after implantation,whereas nonewere affected negatively.
Results to date in the Argus II Retinal Prosthesis System
trial have shown no adverse safety concerns in this group
of 30 subjects. Most SAEs occurred within 6 months
after implantation, and all were treatable with standard
ophthalmic approaches. Most (4/5) late-occurring SAEs
(after 1 year) were part of a cascade of events that had
begun earlier, rather than newly arising events. However,
any implant intended to remain in the eye for many years
carries a long-term risk. Events such as conjunctival
erosion, hypotony, or endophthalmitis could occur in the
long term. Therefore, any patient considering such an
implant should be counseled about the need for regular
(at least once per year) follow-up as long as the implant
remains in the eye.(Second Sight Medical Products, Inc., Sylmar, CA) and
Devices
Comparator Device or Technique
Glaucoma Drainage Device Argus II
10% (5.1e18.4)15 6.7% (0.8e22.1)
11% (6.0e19.1)15 10.0% (2.1e26.5)
5% (1.5e10.6)15; 16% (5.4e33.7)16 10.0% (2.1e26.5)
1% (0.03e5.1)15; 5% (NR)17 10.0% (2.1e26.5)
6.7% (0.8e22.1)
ported for retinal tacks or glaucoma drainage devices for each of 5 serious
for each published reference varies but is typically a mean of 12 months.
1551
Ophthalmology Volume 122, Number 8, August 2015There was 1 explant due to adverse events within 3
years after implantation. In this small study of 30 subjects,
it is difﬁcult to complete a robust statistical analysis of the
safety results because of limited power. There are no long-
term data from other retinal prostheses to place Argus II
system adverse event rates in context. However, the Argus
II is implanted using a series of common vitreoretinal
surgical techniques (e.g., pars plana vitrectomy) and has
design elements in common with other ophthalmic devices,
particularly glaucoma drainage devices and metallic
tacks.14 Therefore, a comparison can be made between
these devices and the Argus II regarding key adverse
event rates, as shown in Table 3, although it should be
noted that the comparison studies included many more
subjects in their analyses.15e18
The comparison indicates that Argus II rates are similar
to those of glaucoma drainage devices and retinal tacks in
most cases. The 1 exception was endophthalmitis, which
was relatively high in the Argus II cohort (10%), although
each of the 3 individual events was culture-negative,
managed successfully by medical (nonsurgical) means,
not related to the sterility of the device, and not associated
with preexisting conjunctival erosion or hypotony. Of note,
2 of the 3 endophthalmitis cases were operated on the same
day at a single site. All 3 cases occurred early in the study
(within 2 months after implantation for each case and
within the ﬁrst year of the overall study start), and no
further cases of endophthalmitis were reported up to 3
years after implantation after several procedural changes
aimed at reducing the risk of infection were implemented.
Changes included adding a temporary cover over the array
portion of the device during the attachment of the extra-
ocular portion of the device on the globe, recommendations
to strengthen the sterile procedures at all surgical centers,
and the addition of prophylactic intravitreal antibiotics at
the end of each case.
Seven subjects underwent elective revision surgeries to
attempt to improve the position of the array. These were
non-SAEs because they were not medically necessary;
however, they were interventions intended to improve the
beneﬁt of the device for these early subjects. No further
elective revision surgeries have been conducted among all
new cases since the last of these in 2010.
Conclusions
It is difﬁcult to reach deﬁnitive conclusions about safety
from this small study. Retinitis pigmentosa is a rare dis-
ease, and patients with almost total loss of vision from RP
are rarer still. With only 30 subjects, statistical power is
low. Among those 30 subjects, however, there were no
lost eyes, all events were treated with standard ophthal-
mological techniques, and there were no unexpected
events. The risk presented by the Argus II also must be
considered in the context of these patients’ profound
blindness and lack of other treatment options. Their vision
before the Argus II was in the range of bare light
perception or less in both eyes. Generally, ophthalmic
adverse events may be a concern because of the possibility
of further vision loss; in these patients, residual vision is1552negligible, thus reducing the risk posed by these adverse
events.
To our knowledge, this study is the largest and longest-
running clinical trial of a retinal prosthesis to date; as of
September 1, 2014, the longest duration of implant was 7.2
years. The results in these 30 subjects indicate that the
Argus II Retinal Prosthesis System has an acceptable risk
proﬁle and is a beneﬁcial therapy for profoundly blind pa-
tients with RP. Earlier results from this trial were the basis
of CE Mark (commercial approval) in Europe. After an
FDA-convened panel of 19 experts voted unanimously that
the beneﬁts outweighed the risks of the Argus II System, the
FDA approved the System for market under the Humani-
tarian Device Exemption in the United States.
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A 66-year-old woman had a ﬂeshy nodule on her upper
eyelid measuring 3 mm in diameter. The lesion was painless
and had been slowly growing for a few years (Fig 1). His-
tologic examination revealed skin with a well-circumscribed
and vascularized dermal nodule. The tumor cells are ar-
ranged in short fascicles separated by artifactual clefting, have
wavy hyperchromatic nuclei, and pale eosinophilic cytoplasm
(Fig 2). To our knowledge, only 3 previous cases of this
benign tumor have been reported in the literature.
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